search
Back to results

26 Week Efficacy and Safety Trial for Patients With Chronic Idiopathic Constipation

Primary Purpose

Chronic Idiopathic Constipation

Status
Terminated
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
Elobixibat 10 mg
Elobixibat 5 mg
Placebo
Sponsored by
Ferring Pharmaceuticals
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Chronic Idiopathic Constipation

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Body mass index (BMI) ≥18.5 but <35.0 kg/m^2
  • Male or female ≥18 years of age
  • Reports <3 spontaneous Bowel movements (BM) per week and reports one or more of the following symptoms for the last 3 months with symptom onset at least 6 months before the Screening Visit or before starting chronic therapy with any laxative:

    1. Straining during at least 25% of defecations
    2. Lumpy or hard stools during at least 25% of defecations
    3. Sensation of incomplete evacuation during at least 25% of defecations
  • Is ambulatory and community dwelling
  • An initial colonoscopy is required if recommended by national guidelines

Exclusion Criteria:

  • Reports loose (mushy) or watery stools in the absence of any laxative intake in the form of a tablet, a suppository or an enema, or prohibited medicine for >25% of BMs
  • The patient reports a BSFS of 6 or 7 during the Pretreatment Period
  • Has irritable bowel syndrome (IBS) with pain/discomfort as predominant symptoms
  • Has a structural abnormality of the GI tract or a disease or condition that can affect Gastrointestinal (GI) motility
  • Has a history of diverticulitis, chronic pancreatitis, active peptic ulcer disease (PUD) not adequately treated, ischaemic colitis, inflammatory bowel disease, laxative abuse, faecal impaction that required hospitalization or emergency treatment, pseudo-obstruction, megacolon, megarectum, bowel obstruction, descending perineum syndrome, ovarian cysts, endometriosis, solitary rectal ulcer syndrome, systemic sclerosis, pre-malignant colonic disease (e.g., familial adenomatous polyposis or hereditary non-polyposis colorectal cancer) or other forms of familial colorectal cancer.
  • Has unexplained and clinically significant GI alarm signals (e.g., lower GI bleeding or heme-positive stool in the absence of known internal or external haemorrhoids, iron-deficiency anaemia, unexplained weight loss) or systemic signs of infection or colitis
  • Has a potential central nervous system (CNS) cause of constipation (e.g., Parkinson's disease, spinal cord injury, multiple sclerosis)
  • Has intestinal/rectal prolapse or other known pelvic floor dysfunction
  • Commonly uses digital manoeuvres (perianal pressure or digital disimpaction) or vaginal splinting to facilitate the passage of a bowel movement
  • Has a history of diabetic neuropathy
  • Has a history of bariatric surgery for treatment of obesity; surgery to remove a segment of the GI tract; or surgery of the abdomen, pelvic or retroperitoneal area during the 6 months prior to Screening; or appendectomy or cholecystectomy 3 months prior to screening; or other major surgery 1 month prior to Screening
  • Has a history of cancer with last date of proven disease activity/presence of malignancy within 5 years, except for adequately treated basal cell carcinoma of the skin, cervical dysplasia, or carcinoma in situ of the skin or the cervix
  • Known human immunodeficiency virus (HIV) or Hepatitis B/C (HBV/HCV) infection
  • Has a history of hospitalization for any psychiatric disorder, or any suicide attempt in the 2 years prior to Screening
  • Is actively abusing alcohol or drugs or has a history of alcohol or drug abuse during the 6 months prior to Screening
  • Is being treated for hypothyroidism, but the dose of medication has not been stable for at least 3 months at the time of Screening
  • Is a pregnant, breast-feeding, or lactating woman

Sites / Locations

  • Alabama Clinical Therapeutics
  • G and L Research, LLC
  • Adobe Gastroenterology Research, LLC
  • Skyline Research LLC
  • GW Research, Inc.
  • Paradigm Clinical, Inc.
  • Providence Clinical Research
  • Stamford Therapeutics Consortium
  • Pulmonary Associates of Brandon
  • In Vivo Clinical Research, Inc.
  • Medsearch Professional Group, Inc.
  • The Community Research of South Florida
  • Center for Gastrointestinal Disorders
  • Nature Coast Clinical Research, LLC
  • Gastroenterology and Hepatology Associates
  • Jupiter Research Inc.
  • Center for Advanced Gastroenterology
  • Advanced Pharma CR, LLC
  • Research Institute of South Florida
  • Gastroenterology Group of Naples
  • Palm Beach Research Center
  • Georgia Clinical Research
  • Elite Clinical Trials, Inc.
  • MediSphere Medical Research Center, LLC
  • MidAtlantic Medical Research Centers, Philip J. Bean Medical Center
  • Boston Clinical Trials
  • University of Michigan Health System
  • Midwest Gastroenterology Partners
  • Advanced Biomedical Research of America
  • ActivMed Practices and Research, Inc.
  • HOSC, Inc.
  • North American Partners in Pain Management
  • Carolina Digestive Health Associates, PA
  • Cumberland Research Associates, LLC
  • Gastroenterology Research Consultants of Greater Cincinnati
  • Hometown Urgent Care and Occupational Health
  • Oklahoma Foundation for Digestive Research
  • Clinical Trials Research Services, LLC
  • Mainline Gastroenterology Associates
  • ClinSearch
  • Memphis Gastroenterology Group, PC
  • KRK Medical Research
  • Research Across America
  • Pioneer Research Solutions, Inc.
  • Pioneer Research Solutions, Inc.
  • Northwest Gastroenterology Associates
  • Cliniques Universitaires Saint Luc
  • Huisartspraktijk Jaak Mortelmans
  • Universitair Ziekenhuis Leuven
  • Hospital de Clinicas de Porto Alegre
  • Faculdade de Medicina do ABC
  • Escola Paulista de Medicina, Universidade Federal de São Paulo
  • John Buhler Research Center
  • Maritime Medical Research Center
  • Prime Health Clinical Research Organization
  • Alpha Clinical Research LLC
  • Rhodin Recherche Clinique
  • Derma Plus s.r.o.
  • Gastroenterologie, s. r. o.
  • Nemocnice Valasske Mezirici a.s., Gastroenterologicka ambulance
  • Klinikum der Universität München-Großhadern
  • Synexus Clinical Research GmbH
  • Elbe Klinikum Stade - Buxtehude GmbH
  • Synexus Clinical Research GmbH
  • Synexus Clinical Research GmbH
  • Emovis GmbH
  • Synexus Clinical Research GmbH
  • Universitätsklinik Charité, Campus Mitte
  • Israelitisches Krankenhaus Hamburg
  • Soroka University Medical Center
  • Bnai Zion Medical Center
  • Hadassah Medical Organization, Ein Kerem
  • Kaplan Medical Center
  • Sheba Medical Center
  • Assaf Harofeh Medical Centre
  • SPZOZ Uniwersytecki Szpital Kliniczny nr 5 im. Gen. Dyw. B. Szareckiego, Uniwersytetu Medycznego
  • Szpital Wojewódzki w Opolu
  • Centrum Medyczne sw. Lukasza Sp. z o.o.
  • Neuro-Care NZOZ
  • Pomorski Uniwersytet Medyczny
  • Global Clinical Trials
  • Boanerges Clinical Research
  • Synexus Clinical Research SA
  • Parklands Medical Centre
  • Boland Ethical Research Group
  • The Memory Centre
  • Langeberg Clinical Trials
  • Newtown Clinical Research Centre
  • Synexus Midlands Clinical Research Centre
  • County Durham and Darlington NHS Foundation Trust
  • Synexus Manchester Clinical Research Centre
  • Tayside University Hospitals NHS Trust, Ninewells Hospital and Medical School
  • Synexus Wales Clinical Research Centre
  • Nottingham University Hospitals NHS Trust

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Placebo Comparator

Arm Label

EBX 10

EBX 5

PLCBO

Arm Description

Elobixibat 10 mg/day

Elobixibat 5 mg/day

Placebo

Outcomes

Primary Outcome Measures

Overall Complete Spontaneous Bowel Movement (CSBM) Response
This outcome measured the percentage of patients who were CSBM responders. A CSBM responder was defined as a patient with ≥3 CSBMs per week and an increase of ≥1 CSBM per week from Baseline, for at least 9 of the 12 weeks in the 12-week Treatment Period, including at least 3 weeks during Weeks 9-12.

Secondary Outcome Measures

Occurrence of CSBM Response
This outcome measured the percentage of patients who had a CSBM within 24 hours after the first dose of treatment. A CSBM was defined as a spontaneous (occurring without laxative within the preceding 24 hours, including no rescue medication within the preceding 24 hours) bowel movement (as interpreted by the patient, with a beginning and an end, including single or multiple stools), accompanied by a patient reported sense of complete evacuation ('complete').
Change From Baseline in Weekly Frequency of Spontaneous Bowel Movements (SBMs)
The change from Baseline for the continuous variable was estimated using a repeated measures analysis of covariance (ANCOVA) model.
Change From Baseline in Weekly Stool Consistency of SBMs
The stool consistency is measured using the seven-point ordinal Bristol Stool Form Scale (BSFS) score. The BSFS classifies human stool into seven types and points them accordingly. Type 1: Separate hard lumps, like nuts (hard to pass) Type 2: Sausage-shaped, but lumpy Type 3: Like a sausage but with cracks on its surface Type 4: Like a sausage or snake, smooth and soft Type 5: Soft blobs with clear cut edges (passed easily) Type 6: Fluffy pieces with ragged edges, a mushy stool Type 7: Watery, no solid pieces, entirely liquid Types 1 and 2 indicate constipation, with 3 and 4 represents the ideal stool form (especially the latter), and 5, 6 and 7 tends towards diarrhoea . For a given assessment week, the weekly stool consistency was defined as the sum of non-missing stool consistency score for SBMs during that week divided by the number of non-missing stool consistency score for SBMs during that week. The parameter was analysed using repeated measures ANCOVA model.
Total Patient Assessment of Constipation - Quality of Life (PAC-QOL) Score Responder
This outcome measured the percentage of patients who were PAC-QOL score responder at 12-week of Treatment Period. A PAC-QOL score responder was defined as a patient with ≥50% reduction in total PAC-QOL score from Baseline at Week 12. PAC-QOL is a 28-item questionnaire for psychometric assessment of disease-specific quality of life. The questionnaire is based on 5-point Likert scale; ranging from 0 [none of the time or not at all] to 4 [all of the time or extremely]). A lower score indicates a better Quality of Life. The PAC-QOL questionnaire is developed specifically for patients with constipation. Total PAC-QOL score was averaged from the individual item score.
Change From Baseline in Weekly Degree of Straining of SBMs
The degree of straining was measured using the five-point ordinal scale (1=Not at all, 2=A little bit, 3=A moderate amount, 4=A great deal, and 5=An extreme amount). For a given assessment week, the weekly degree of straining was defined as the sum of non-missing straining score for SBMs during that week divided by the number of non-missing straining score for SBMs during that week. The parameter was analysed using repeated measures ANCOVA model.
Change From Baseline in Weekly Abdominal Bloating Score
The abdominal bloating score was measured using the five-point ordinal scale (1=None, 2=Mild, 3=Moderate, 4=Severe, and 5=Very severe). For a given assessment week, the weekly abdominal bloating score was defined as the sum of non-missing abdominal bloating score for SBMs during that week divided by the number of non-missing abdominal bloating score for SBMs during that week. The parameter was analysed using repeated measures ANCOVA model.
Change From Baseline in Weekly Abdominal Discomfort Score
The abdominal discomfort score was measured using the five-point ordinal scale (1=None, 2=Mild, 3=Moderate, 4=Severe, and 5=Very severe). For a given assessment week, the weekly abdominal discomfort score was defined as the sum of non-missing abdominal discomfort score for SBMs during that week divided by the number of non-missing abdominal discomfort score for SBMs during that week. The parameter was analysed using repeated measures ANCOVA model.

Full Information

First Posted
April 5, 2013
Last Updated
September 22, 2015
Sponsor
Ferring Pharmaceuticals
search

1. Study Identification

Unique Protocol Identification Number
NCT01827592
Brief Title
26 Week Efficacy and Safety Trial for Patients With Chronic Idiopathic Constipation
Official Title
A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients With Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 26 Weeks
Study Type
Interventional

2. Study Status

Record Verification Date
September 2015
Overall Recruitment Status
Terminated
Why Stopped
Terminated due to a distribution issue with the trial medication
Study Start Date
April 2013 (undefined)
Primary Completion Date
March 2014 (Actual)
Study Completion Date
May 2014 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Ferring Pharmaceuticals

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Efficacy and Safety Trial of elobixibat in Patients with Chronic Idiopathic Constipation treated for 26 Weeks.
Detailed Description
The present trial was designed to determine the efficacy and safety of elobixibat treatment (at both doses of 5 mg and 10 mg/day) compared to placebo treatment for 26-week Treatment Period in patients with chronic idiopathic constipation. Patients were followed-up for 2 weeks after end of the Treatment Period. The assessment of primary and key secondary end points was done for patients who completed the first 12 weeks of Treatment Period. Incidence of Adverse Events (AEs) were reported till 2 weeks after end of the treatment. The trial was early terminated due to a distribution issue with the trial medication.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Chronic Idiopathic Constipation

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
376 (Actual)

8. Arms, Groups, and Interventions

Arm Title
EBX 10
Arm Type
Experimental
Arm Description
Elobixibat 10 mg/day
Arm Title
EBX 5
Arm Type
Experimental
Arm Description
Elobixibat 5 mg/day
Arm Title
PLCBO
Arm Type
Placebo Comparator
Arm Description
Placebo
Intervention Type
Drug
Intervention Name(s)
Elobixibat 10 mg
Other Intervention Name(s)
A3309
Intervention Description
Elobixibat 10 mg/day
Intervention Type
Drug
Intervention Name(s)
Elobixibat 5 mg
Other Intervention Name(s)
A3309
Intervention Description
Elobixibat 5 mg/day
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Placebo
Primary Outcome Measure Information:
Title
Overall Complete Spontaneous Bowel Movement (CSBM) Response
Description
This outcome measured the percentage of patients who were CSBM responders. A CSBM responder was defined as a patient with ≥3 CSBMs per week and an increase of ≥1 CSBM per week from Baseline, for at least 9 of the 12 weeks in the 12-week Treatment Period, including at least 3 weeks during Weeks 9-12.
Time Frame
During the first 12 weeks
Secondary Outcome Measure Information:
Title
Occurrence of CSBM Response
Description
This outcome measured the percentage of patients who had a CSBM within 24 hours after the first dose of treatment. A CSBM was defined as a spontaneous (occurring without laxative within the preceding 24 hours, including no rescue medication within the preceding 24 hours) bowel movement (as interpreted by the patient, with a beginning and an end, including single or multiple stools), accompanied by a patient reported sense of complete evacuation ('complete').
Time Frame
Within the first 24 hours of treatment initiation
Title
Change From Baseline in Weekly Frequency of Spontaneous Bowel Movements (SBMs)
Description
The change from Baseline for the continuous variable was estimated using a repeated measures analysis of covariance (ANCOVA) model.
Time Frame
From Baseline (2-week Pretreatment Period) to overall first 12-weeks of Treatment Period
Title
Change From Baseline in Weekly Stool Consistency of SBMs
Description
The stool consistency is measured using the seven-point ordinal Bristol Stool Form Scale (BSFS) score. The BSFS classifies human stool into seven types and points them accordingly. Type 1: Separate hard lumps, like nuts (hard to pass) Type 2: Sausage-shaped, but lumpy Type 3: Like a sausage but with cracks on its surface Type 4: Like a sausage or snake, smooth and soft Type 5: Soft blobs with clear cut edges (passed easily) Type 6: Fluffy pieces with ragged edges, a mushy stool Type 7: Watery, no solid pieces, entirely liquid Types 1 and 2 indicate constipation, with 3 and 4 represents the ideal stool form (especially the latter), and 5, 6 and 7 tends towards diarrhoea . For a given assessment week, the weekly stool consistency was defined as the sum of non-missing stool consistency score for SBMs during that week divided by the number of non-missing stool consistency score for SBMs during that week. The parameter was analysed using repeated measures ANCOVA model.
Time Frame
From Baseline (2-week Pretreatment Period) to overall first 12-weeks of Treatment Period
Title
Total Patient Assessment of Constipation - Quality of Life (PAC-QOL) Score Responder
Description
This outcome measured the percentage of patients who were PAC-QOL score responder at 12-week of Treatment Period. A PAC-QOL score responder was defined as a patient with ≥50% reduction in total PAC-QOL score from Baseline at Week 12. PAC-QOL is a 28-item questionnaire for psychometric assessment of disease-specific quality of life. The questionnaire is based on 5-point Likert scale; ranging from 0 [none of the time or not at all] to 4 [all of the time or extremely]). A lower score indicates a better Quality of Life. The PAC-QOL questionnaire is developed specifically for patients with constipation. Total PAC-QOL score was averaged from the individual item score.
Time Frame
At 12 weeks
Title
Change From Baseline in Weekly Degree of Straining of SBMs
Description
The degree of straining was measured using the five-point ordinal scale (1=Not at all, 2=A little bit, 3=A moderate amount, 4=A great deal, and 5=An extreme amount). For a given assessment week, the weekly degree of straining was defined as the sum of non-missing straining score for SBMs during that week divided by the number of non-missing straining score for SBMs during that week. The parameter was analysed using repeated measures ANCOVA model.
Time Frame
From Baseline (2-week Pretreatment Period) to overall first 12-weeks of Treatment Period
Title
Change From Baseline in Weekly Abdominal Bloating Score
Description
The abdominal bloating score was measured using the five-point ordinal scale (1=None, 2=Mild, 3=Moderate, 4=Severe, and 5=Very severe). For a given assessment week, the weekly abdominal bloating score was defined as the sum of non-missing abdominal bloating score for SBMs during that week divided by the number of non-missing abdominal bloating score for SBMs during that week. The parameter was analysed using repeated measures ANCOVA model.
Time Frame
From Baseline (2-week Pretreatment Period) to overall first 12-weeks of Treatment Period
Title
Change From Baseline in Weekly Abdominal Discomfort Score
Description
The abdominal discomfort score was measured using the five-point ordinal scale (1=None, 2=Mild, 3=Moderate, 4=Severe, and 5=Very severe). For a given assessment week, the weekly abdominal discomfort score was defined as the sum of non-missing abdominal discomfort score for SBMs during that week divided by the number of non-missing abdominal discomfort score for SBMs during that week. The parameter was analysed using repeated measures ANCOVA model.
Time Frame
From Baseline (2-week Pretreatment Period) to overall first 12-weeks of Treatment Period

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Body mass index (BMI) ≥18.5 but <35.0 kg/m^2 Male or female ≥18 years of age Reports <3 spontaneous Bowel movements (BM) per week and reports one or more of the following symptoms for the last 3 months with symptom onset at least 6 months before the Screening Visit or before starting chronic therapy with any laxative: Straining during at least 25% of defecations Lumpy or hard stools during at least 25% of defecations Sensation of incomplete evacuation during at least 25% of defecations Is ambulatory and community dwelling An initial colonoscopy is required if recommended by national guidelines Exclusion Criteria: Reports loose (mushy) or watery stools in the absence of any laxative intake in the form of a tablet, a suppository or an enema, or prohibited medicine for >25% of BMs The patient reports a BSFS of 6 or 7 during the Pretreatment Period Has irritable bowel syndrome (IBS) with pain/discomfort as predominant symptoms Has a structural abnormality of the GI tract or a disease or condition that can affect Gastrointestinal (GI) motility Has a history of diverticulitis, chronic pancreatitis, active peptic ulcer disease (PUD) not adequately treated, ischaemic colitis, inflammatory bowel disease, laxative abuse, faecal impaction that required hospitalization or emergency treatment, pseudo-obstruction, megacolon, megarectum, bowel obstruction, descending perineum syndrome, ovarian cysts, endometriosis, solitary rectal ulcer syndrome, systemic sclerosis, pre-malignant colonic disease (e.g., familial adenomatous polyposis or hereditary non-polyposis colorectal cancer) or other forms of familial colorectal cancer. Has unexplained and clinically significant GI alarm signals (e.g., lower GI bleeding or heme-positive stool in the absence of known internal or external haemorrhoids, iron-deficiency anaemia, unexplained weight loss) or systemic signs of infection or colitis Has a potential central nervous system (CNS) cause of constipation (e.g., Parkinson's disease, spinal cord injury, multiple sclerosis) Has intestinal/rectal prolapse or other known pelvic floor dysfunction Commonly uses digital manoeuvres (perianal pressure or digital disimpaction) or vaginal splinting to facilitate the passage of a bowel movement Has a history of diabetic neuropathy Has a history of bariatric surgery for treatment of obesity; surgery to remove a segment of the GI tract; or surgery of the abdomen, pelvic or retroperitoneal area during the 6 months prior to Screening; or appendectomy or cholecystectomy 3 months prior to screening; or other major surgery 1 month prior to Screening Has a history of cancer with last date of proven disease activity/presence of malignancy within 5 years, except for adequately treated basal cell carcinoma of the skin, cervical dysplasia, or carcinoma in situ of the skin or the cervix Known human immunodeficiency virus (HIV) or Hepatitis B/C (HBV/HCV) infection Has a history of hospitalization for any psychiatric disorder, or any suicide attempt in the 2 years prior to Screening Is actively abusing alcohol or drugs or has a history of alcohol or drug abuse during the 6 months prior to Screening Is being treated for hypothyroidism, but the dose of medication has not been stable for at least 3 months at the time of Screening Is a pregnant, breast-feeding, or lactating woman
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Clinical Development Support
Organizational Affiliation
Ferring Pharmaceuticals
Official's Role
Study Director
Facility Information:
Facility Name
Alabama Clinical Therapeutics
City
Birmingham
State/Province
Alabama
Country
United States
Facility Name
G and L Research, LLC
City
Foley
State/Province
Alabama
Country
United States
Facility Name
Adobe Gastroenterology Research, LLC
City
Tucson
State/Province
Arizona
Country
United States
Facility Name
Skyline Research LLC
City
Cerritos
State/Province
California
Country
United States
Facility Name
GW Research, Inc.
City
Chula Vista
State/Province
California
Country
United States
Facility Name
Paradigm Clinical, Inc.
City
Garden Grove
State/Province
California
Country
United States
Facility Name
Providence Clinical Research
City
North Hollywood
State/Province
California
Country
United States
Facility Name
Stamford Therapeutics Consortium
City
Stamford
State/Province
Connecticut
Country
United States
Facility Name
Pulmonary Associates of Brandon
City
Brandon
State/Province
Florida
Country
United States
Facility Name
In Vivo Clinical Research, Inc.
City
Hialeah
State/Province
Florida
Country
United States
Facility Name
Medsearch Professional Group, Inc.
City
Hialeah
State/Province
Florida
Country
United States
Facility Name
The Community Research of South Florida
City
Hialeah
State/Province
Florida
Country
United States
Facility Name
Center for Gastrointestinal Disorders
City
Hollywood
State/Province
Florida
Country
United States
Facility Name
Nature Coast Clinical Research, LLC
City
Inverness
State/Province
Florida
Country
United States
Facility Name
Gastroenterology and Hepatology Associates
City
Jacksonville
State/Province
Florida
Country
United States
Facility Name
Jupiter Research Inc.
City
Jupiter
State/Province
Florida
Country
United States
Facility Name
Center for Advanced Gastroenterology
City
Maitland
State/Province
Florida
Country
United States
Facility Name
Advanced Pharma CR, LLC
City
Miami
State/Province
Florida
Country
United States
Facility Name
Research Institute of South Florida
City
Miami
State/Province
Florida
Country
United States
Facility Name
Gastroenterology Group of Naples
City
Naples
State/Province
Florida
Country
United States
Facility Name
Palm Beach Research Center
City
West Palm Beach
State/Province
Florida
Country
United States
Facility Name
Georgia Clinical Research
City
Snellville
State/Province
Georgia
Country
United States
Facility Name
Elite Clinical Trials, Inc.
City
Blackfoot
State/Province
Idaho
Country
United States
Facility Name
MediSphere Medical Research Center, LLC
City
Evansville
State/Province
Indiana
Country
United States
Facility Name
MidAtlantic Medical Research Centers, Philip J. Bean Medical Center
City
Hollywood
State/Province
Maryland
Country
United States
Facility Name
Boston Clinical Trials
City
Boston
State/Province
Massachusetts
Country
United States
Facility Name
University of Michigan Health System
City
Ann Arbor
State/Province
Michigan
Country
United States
Facility Name
Midwest Gastroenterology Partners
City
Lee's Summit
State/Province
Missouri
Country
United States
Facility Name
Advanced Biomedical Research of America
City
Las Vegas
State/Province
Nevada
Country
United States
Facility Name
ActivMed Practices and Research, Inc.
City
Newington
State/Province
New Hampshire
Country
United States
Facility Name
HOSC, Inc.
City
Brooklyn
State/Province
New York
Country
United States
Facility Name
North American Partners in Pain Management
City
Valley Stream
State/Province
New York
Country
United States
Facility Name
Carolina Digestive Health Associates, PA
City
Davidson
State/Province
North Carolina
Country
United States
Facility Name
Cumberland Research Associates, LLC
City
Fayetteville
State/Province
North Carolina
Country
United States
Facility Name
Gastroenterology Research Consultants of Greater Cincinnati
City
Cincinnati
State/Province
Ohio
Country
United States
Facility Name
Hometown Urgent Care and Occupational Health
City
Groveport
State/Province
Ohio
Country
United States
Facility Name
Oklahoma Foundation for Digestive Research
City
Oklahoma City
State/Province
Oklahoma
Country
United States
Facility Name
Clinical Trials Research Services, LLC
City
Pittsburgh
State/Province
Pennsylvania
Country
United States
Facility Name
Mainline Gastroenterology Associates
City
Souderton
State/Province
Pennsylvania
Country
United States
Facility Name
ClinSearch
City
Chattanooga
State/Province
Tennessee
Country
United States
Facility Name
Memphis Gastroenterology Group, PC
City
Germantown
State/Province
Tennessee
Country
United States
Facility Name
KRK Medical Research
City
Dallas
State/Province
Texas
Country
United States
Facility Name
Research Across America
City
Dallas
State/Province
Texas
Country
United States
Facility Name
Pioneer Research Solutions, Inc.
City
Houston
State/Province
Texas
Country
United States
Facility Name
Pioneer Research Solutions, Inc.
City
Sugar Land
State/Province
Texas
Country
United States
Facility Name
Northwest Gastroenterology Associates
City
Bellevue
State/Province
Washington
Country
United States
Facility Name
Cliniques Universitaires Saint Luc
City
Brussels
Country
Belgium
Facility Name
Huisartspraktijk Jaak Mortelmans
City
Ham
Country
Belgium
Facility Name
Universitair Ziekenhuis Leuven
City
Leuven
Country
Belgium
Facility Name
Hospital de Clinicas de Porto Alegre
City
Porto Alegre
State/Province
Rio Grande do Sul
Country
Brazil
Facility Name
Faculdade de Medicina do ABC
City
Sant André
State/Province
São Paulo
Country
Brazil
Facility Name
Escola Paulista de Medicina, Universidade Federal de São Paulo
City
São Paulo
Country
Brazil
Facility Name
John Buhler Research Center
City
Winnipeg
State/Province
Manitoba
Country
Canada
Facility Name
Maritime Medical Research Center
City
Bathurst
State/Province
New Brunswick
Country
Canada
Facility Name
Prime Health Clinical Research Organization
City
Toronto
State/Province
Ontario
Country
Canada
Facility Name
Alpha Clinical Research LLC
City
Québec
State/Province
Quebec
Country
Canada
Facility Name
Rhodin Recherche Clinique
City
DrummondvilleQC
Country
Canada
Facility Name
Derma Plus s.r.o.
City
Ceské Budejovice
Country
Czech Republic
Facility Name
Gastroenterologie, s. r. o.
City
Hradec Králové
Country
Czech Republic
Facility Name
Nemocnice Valasske Mezirici a.s., Gastroenterologicka ambulance
City
Valasske Mezirici
Country
Czech Republic
Facility Name
Klinikum der Universität München-Großhadern
City
München
State/Province
Bavaria
Country
Germany
Facility Name
Synexus Clinical Research GmbH
City
Frankfurt am Main
State/Province
Hessen
Country
Germany
Facility Name
Elbe Klinikum Stade - Buxtehude GmbH
City
Stade
State/Province
Niedersachsen
Country
Germany
Facility Name
Synexus Clinical Research GmbH
City
Bochum
State/Province
Nordrhein-westfalen
Country
Germany
Facility Name
Synexus Clinical Research GmbH
City
Leipzig
State/Province
Sachsen
Country
Germany
Facility Name
Emovis GmbH
City
Berlin
Country
Germany
Facility Name
Synexus Clinical Research GmbH
City
Berlin
Country
Germany
Facility Name
Universitätsklinik Charité, Campus Mitte
City
Berlin
Country
Germany
Facility Name
Israelitisches Krankenhaus Hamburg
City
Hamburg
Country
Germany
Facility Name
Soroka University Medical Center
City
Beer-Sheva
Country
Israel
Facility Name
Bnai Zion Medical Center
City
Haifa
Country
Israel
Facility Name
Hadassah Medical Organization, Ein Kerem
City
Jerusalem
Country
Israel
Facility Name
Kaplan Medical Center
City
Rehovot
Country
Israel
Facility Name
Sheba Medical Center
City
Tel Hashomer
Country
Israel
Facility Name
Assaf Harofeh Medical Centre
City
Zerifin
Country
Israel
Facility Name
SPZOZ Uniwersytecki Szpital Kliniczny nr 5 im. Gen. Dyw. B. Szareckiego, Uniwersytetu Medycznego
City
Lódz
State/Province
Lodzkie
Country
Poland
Facility Name
Szpital Wojewódzki w Opolu
City
Opole
State/Province
Opolskie
Country
Poland
Facility Name
Centrum Medyczne sw. Lukasza Sp. z o.o.
City
Czestochowa
State/Province
Slaskie
Country
Poland
Facility Name
Neuro-Care NZOZ
City
Katowice
State/Province
Slaskie
Country
Poland
Facility Name
Pomorski Uniwersytet Medyczny
City
Szczecin
State/Province
Zachodniopomorskie
Country
Poland
Facility Name
Global Clinical Trials
City
Port Elizabeth
State/Province
Eastern Cape
Country
South Africa
Facility Name
Boanerges Clinical Research
City
Bloemfontein
State/Province
Free State
Country
South Africa
Facility Name
Synexus Clinical Research SA
City
Pretoria
State/Province
Gauteng
Country
South Africa
Facility Name
Parklands Medical Centre
City
Durban
State/Province
KwaZulu-Natal
Country
South Africa
Facility Name
Boland Ethical Research Group
City
Worcester
State/Province
Western Cape
Country
South Africa
Facility Name
The Memory Centre
City
Johannesburg
Country
South Africa
Facility Name
Langeberg Clinical Trials
City
Kraaifontein
Country
South Africa
Facility Name
Newtown Clinical Research Centre
City
Newtown
Country
South Africa
Facility Name
Synexus Midlands Clinical Research Centre
City
Birmingham
State/Province
England
Country
United Kingdom
Facility Name
County Durham and Darlington NHS Foundation Trust
City
Durham
State/Province
England
Country
United Kingdom
Facility Name
Synexus Manchester Clinical Research Centre
City
Manchester
State/Province
England
Country
United Kingdom
Facility Name
Tayside University Hospitals NHS Trust, Ninewells Hospital and Medical School
City
Dundee
State/Province
Scotland
Country
United Kingdom
Facility Name
Synexus Wales Clinical Research Centre
City
Cardiff
State/Province
Wales
Country
United Kingdom
Facility Name
Nottingham University Hospitals NHS Trust
City
Nottingham
Country
United Kingdom

12. IPD Sharing Statement

Learn more about this trial

26 Week Efficacy and Safety Trial for Patients With Chronic Idiopathic Constipation

We'll reach out to this number within 24 hrs